Clariscan Use In Pregnancy & Lactation

Pregnancy: Data on the use of gadolinium-based contrast agents including gadoteric acid in pregnant women is limited. Gadolinium can cross the placenta. It is unknown whether exposure to gadolinium is associated with adverse effects in the foetus.
Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see Pharmacology: Toxicology: Preclinical safety data under Actions). Gadoteric Acid (Clariscan) should not be used during pregnancy unless the clinical condition of the woman requires use of gadoteric acid.
Breastfeeding: Gadolinium containing contrast agents are excreted into breast milk in very small amounts (see Pharmacology: Toxicology: Preclinical safety data under Actions). At clinical doses, no effects on the infant are anticipated due to the small amount excreted in milk and poor absorption from the gut. Continuing or discontinuing breast feeding for a period of 24 hours after administration of Gadoteric Acid (Clariscan), should be at the discretion of the doctor and lactating mother.
Fertility: There are no clinical data available with regard to effects on fertility.